z-logo
Premium
Antiresorptive agents' bone‐protective and adjuvant effects in postmenopausal women with early breast cancer
Author(s) -
Chukir Tariq,
Liu Yi,
Farooki Azeez
Publication year - 2019
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.13834
Subject(s) - denosumab , medicine , breast cancer , discontinuation , bisphosphonate , adjuvant , bone resorption , oncology , bone mineral , cancer , clinical trial , bone density conservation agents , osteoporosis , pharmacology
Potent antiresorptive drugs (bisphosphonate and denosumab) are often used to protect bone health in postmenopausal breast cancer patients. In addition, clinical trials have shown that these drugs increase disease‐free survival, though the mechanism of adjuvant benefit is largely unknown. Here we review the bone health and adjuvant data for both classes of antiresorptive drugs and highlight differences in their pharmacology. Inhibition of bone resorption is vitally important to protect against osteoporotic fractures, and may also contribute to adjuvant survival benefits by making the bone microenvironment less amenable to breast cancer metastasis. After a course of therapy, stoppage of bisphosphonates yields a persistent antiresorptive effect, whereas discontinuation of denosumab causes a rebound increase in bone resorption markers and a loss of bone mineral density to baseline levels. Whether the potential adjuvant benefits of denosumab are also rapidly lost after drug discontinuation deserves further investigation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here